Alliance Pharma PLC Further update on timing of preliminary results
22 Aprile 2024 - 8:00AM
RNS Regulatory News
RNS Number : 4157L
Alliance Pharma PLC
22 April 2024
For
immediate release
|
22 April
2024
|
ALLIANCE
PHARMA
("Alliance", "Company" or the
"Group")
Further update on timing of preliminary
results announcement
Alliance Pharma plc (AIM: APH), the
international healthcare group, announces that the preliminary
results for the year ended 31 December 2023 will not be published
on 23 April 2024. We now anticipate that the results will be
published in early May, and we expect to provide an update on the
date of publication on 26 April 2024.
Further to the announcement on 5
April 2024, whilst the audit of the results is at an advanced
stage, the Group's auditor, Deloitte LLP, has requested additional
time to finalise its work.
Alliance reiterates that the details
provided in the full year trading update on 29 January 2024 remain
accurate.
For
further information:
Alliance Pharma plc
|
+ 44 (0)1249
466966
|
Cora McCallum, Head of Investor
Relations & Corporate Communications
|
+ 44
(0)1249 705168
|
ir@allianceph.com
|
|
|
|
Buchanan
|
+ 44 (0)20 7466
5000
|
Mark Court / Sophie Wills
|
|
alliancepharma@buchanan.uk.com
|
|
|
|
Deutsche Numis (Nominated Adviser and Joint
Broker)
|
+ 44 (0)20 7260
1000
|
Freddie Barnfield / Duncan Monteith
/ Sher Shah
|
|
|
|
Investec Bank plc (Joint Broker)
|
+ 44 (0)20 7597
5970
|
Patrick Robb / Maria Gomez de
Olea
|
|
About Alliance
Alliance Pharma plc (AIM: APH) is a
growing consumer healthcare company. Our purpose is to empower
people to make a positive difference to their health and wellbeing
by making our trusted and proven brands available around the
world.
We deliver organic growth through
investing in our priority brands and channels, in related
innovation, and through selective geographic expansion to increase
the reach of our brands. Periodically, we may look to enhance our
organic growth through selective, complementary
acquisitions.
Headquartered in the UK, the Group
employs around 285 people based in locations across Europe, North
America, and the Asia Pacific region. By outsourcing our
manufacturing and logistics we remain asset-light and focused on
maximising the value we can bring, both to our stakeholders and to
our brands.
For more information on Alliance,
please visit our website: www.alliancepharmaceuticals.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
FURZZGZDRMMGDZM
Grafico Azioni Alliance Pharma (LSE:APH)
Storico
Da Mar 2025 a Mar 2025
Grafico Azioni Alliance Pharma (LSE:APH)
Storico
Da Mar 2024 a Mar 2025